Page last updated: 2024-09-04

torcetrapib and Obesity

torcetrapib has been researched along with Obesity in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Burnier, M; Vogt, B1
André, A; Briand, F; Ouguerram, K; Sulpice, T; Thieblemont, Q1

Reviews

1 review(s) available for torcetrapib and Obesity

ArticleYear
Aldosterone and cardiovascular risk.
    Current hypertension reports, 2009, Volume: 11, Issue:6

    Topics: Aldosterone; Antihypertensive Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Humans; Hyperaldosteronism; Kidney Diseases; Metabolic Syndrome; Obesity; Quinolines

2009

Other Studies

1 other study(ies) available for torcetrapib and Obesity

ArticleYear
CETP inhibitor torcetrapib promotes reverse cholesterol transport in obese insulin-resistant CETP-ApoB100 transgenic mice.
    Clinical and translational science, 2011, Volume: 4, Issue:6

    Topics: Animals; Anticholesteremic Agents; Apolipoprotein B-100; Bile Acids and Salts; Biological Transport; Body Weight; Cells, Cultured; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Dyslipidemias; Humans; Insulin Resistance; Lipoproteins; Macrophages; Male; Mice; Mice, Transgenic; Obesity; Quinolines

2011